Pezhman Roohani, who leads a major teleneurology program, has described how GLP-1 receptor agonists may change treatment for several brain disorders. He also warned that long-term risks and choosing the right patients require careful attention.
GLP-1 drugs show promise beyond diabetes and obesity
Roohani, medical director of the teleneurology and telestroke program at Allina Health, spoke on the Mind Moments podcast. The drugs are now being tested for stroke prevention, neurodegenerative diseases, and idiopathic intracranial hypertension.
In the interview, he cited recent Alzheimer’s disease trial results as a key development. The drugs did not reverse cognitive decline in advanced cases, but the findings point to a possible role in prevention and early treatment. Scientists are now trying to determine which patients might benefit most.
Prevention and patient subgroups take center stage
The discussion moved to practical challenges. Roohani listed muscle loss, nutritional deficiencies, and the importance of lifestyle changes as major concerns with long-term use. Clinicians may also need to adapt their counseling when prescribing these drugs for neurologic conditions, where patients often face mobility or cognitive difficulties.
Related: Website Users Unable to Access Content After Blocking
Research into neuroinflammation, traumatic brain injury, and addiction is also underway. The ability of these drugs to cross the blood-brain barrier has raised interest in their potential to influence brain chemistry. Most applications remain experimental, though stroke prevention is the furthest along in testing.
It remains unclear whether the drugs help neurologic conditions through metabolic effects like better blood sugar control and weight loss or through direct action on brain cells. Roohani said both factors might contribute, but more focused research is needed to understand their roles.
Trials and regulatory steps
No GLP-1 drug has received FDA approval for a neurologic use yet, but the field is advancing rapidly.
For now, doctors must balance the drugs’ potential against known side effects. These include gastrointestinal issues and rare but serious complications like pancreatitis. Roohani said selecting the right patients is especially important for those with pre-existing conditions that weight loss or metabolic changes could worsen.
Related: Patients left at risk by poor communication standards
The conversation also covered broader implications for neurology. If GLP-1 drugs prove effective for brain disorders, they could join other repurposed medications, such as certain diabetes treatments used in Parkinson’s. This shift might lead to more integrated care, with neurologists and endocrinologists working together more often.
Patients face uncertainty as well. Roohani recommended discussing risks and benefits with a provider, particularly for those with a history of muscle loss, eating disorders, or other complicating factors.
Research continues to focus on prevention rather than reversal. If these drugs can delay neurodegenerative diseases by even a few years, the public health impact could be significant. However, that outcome remains uncertain.